---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016160"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:22:37.617188+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma concludes BioNTech mRNA collaboration, plans Phase 3 trial for MAT2203 antifungal

## Summary
- BioNTech oral mRNA collaboration ended; in vivo oral study showed no activity, but systemic delivery and stability demonstrated.
- Company plans to submit revised Phase 3 trial design for MAT2203 in aspergillosis and other IFIs in Q2 2023.
- Seven patients with IFIs treated under compassionate use; oral MAT2203 showed safety and efficacy in diverse infections.
- Cash position sufficient to fund operations into second half of 2024.
- Expanded collaboration with National Resilience for mRNA/oligonucleotide delivery; initial data expected Q3 2023.

## SEC filing metadata
- accession: 0001493152-23-016160
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315223016160/0001493152-23-016160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315223016160/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016160
- JSON: https://secwatch.observer/filing/0001493152-23-016160.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016160.txt

## Key facts
- Earnings Releases
  Matinas BioPharma Holdings, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 10, 2023, Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315223016160/0001493152-23-016160-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.